Bioline RX Gets European Device Confirmation for Bl-5010 Drug

Bioline RX Ltd. (BLRX) said it received European confirmation for the classification of its BL-5010 drug to treat seborrheic keratosis skin lesions, as a medical device Class IIa, according to a statement filed today with the Tel Aviv Stock Exchange.

To contact the reporter on this story: Sharon Wrobel in Tel Aviv at swrobel4@bloomberg.net

To contact the editor responsible for this story: Calev Ben-David at cbendavid@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.